Hologic (NASDAQ:HOLX) Sets New 1-Year High – Still a Buy?

Hologic, Inc. (NASDAQ:HOLX) shares reached a new 52-week high during trading on Tuesday . The stock traded as high as $75.49 and last traded at $75.3950, with a volume of 308818 shares trading hands. The stock had previously closed at $75.45.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley upped their target price on shares of Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. BNP Paribas Exane cut shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price objective on the stock. in a research note on Friday, November 21st. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Argus downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Two research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Hologic has a consensus rating of “Hold” and a consensus price target of $78.42.

Hologic Stock Down 0.1%

The stock’s 50-day moving average price is $74.96 and its two-hundred day moving average price is $72.22. The stock has a market capitalization of $16.83 billion, a PE ratio of 31.41, a P/E/G ratio of 2.24 and a beta of 0.73. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a return on equity of 19.58% and a net margin of 13.18%.The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the firm earned $0.87 EPS. The business’s revenue for the quarter was up 2.5% on a year-over-year basis. As a group, analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in HOLX. Winnow Wealth LLC purchased a new position in shares of Hologic during the third quarter valued at $26,000. Root Financial Partners LLC purchased a new position in Hologic during the third quarter worth approximately $27,000. Harbor Capital Advisors Inc. purchased a new stake in shares of Hologic during the fourth quarter worth about $27,000. SJS Investment Consulting Inc. lifted its stake in shares of Hologic by 341.5% in the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 362 shares in the last quarter. Finally, Loomis Sayles & Co. L P acquired a new stake in shares of Hologic in the second quarter valued at approximately $33,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.